Copy to clipboard 
Orthofix Medical reported 4Q24 orthopedic sales of $215.7 million, up 7.6% compared to the fourth quarter of 2023. For the full year, the company generated $799.5 million, up 7.1% compared to the prior year.
Sales from Orthofix’s trauma and bone growth therapy businesses were the highest in company history. Placements of the 7D navigation system grew 30% compared to last year, with a 150% increase in the number of earn-out agreements. Additionally, spinal implant sales in the U.S. grew 12% with the top six implant systems growing 24%.
The company decided to phase out the M6 artificial disc, which had become a headwind for sales in recent years.
Despite the product’s Level 2 IDE study, Orthofix did not see increased demand for the line. The M6 line generated $23.4 million in 2024, or just over 5% of the company’s spine-related sales.
“We will also be discontinuing the M6, the artificial cervical disc and the M6L artificial lumbar disc product lines,” said Orthofix CFO Julie Andrews. “This product phaseout is in line with our commitment to direct resources to more profitable growth opportunities. It is another milestone in our transformation and supports our strategic focus on driving profitable growth in areas where we have a differentiated advantage.”
Excluding M6 sales, Orthofix expects revenue between $818 million and $826 million in 2025, representing 6.5% growth at the midpoint.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 4Q24 | 4Q23 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $73.0 | $68.3 | $4.7 | 6.8% |
| Trauma | $35.8 | $30.6 | $5.1 | 16.8% |
| Orthobiologics | $38.3 | $38.3 | ($0.0) | (0%) |
| Enabling Technology | $4.8 | $4.4 | $0.4 | 8.3% |
| Other (Bone Growth Therapies) | $63.9 | $58.8 | $5.1 | 8.6% |
| Total | $215.7 | $200.4 | $15.2 | 7.6% |
| Segment | FY24 | FY23 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $285.9 | $266.3 | $19.6 | 7.4% |
| Trauma | $124.2 | $115.3 | $8.9 | 7.7% |
| Orthobiologics | $143.3 | $141.1 | $2.2 | 1.6% |
| Enabling Technology | $12.6 | $11.3 | $1.3 | 11.3% |
| Other (Bone Growth Therapies) | $233.4 | $212.5 | $20.9 | 9.8% |
| Total | $799.5 | $746.6 | $52.9 | 7.1% |
Orthopedic Sales by Geography
| Region | 4Q24 | 4Q23 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $179.2 | $166.9 | $12.3 | 7.4% |
| OUS | $36.4 | $33.5 | $2.9 | 8.7% |
| EMEA | $15.7 | $14.3 | $1.4 | 10.1% |
| APAC | $14.3 | $12.7 | $1.6 | 12.5% |
| ROW | $6.4 | $6.5 | ($0.1) | (1.6%) |
| Total | $215.7 | $200.4 | $15.2 | 7.6% |
| Region | FY24 | FY23 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $672.8 | $620.8 | $52.0 | 8.4% |
| OUS | $126.7 | $125.8 | $0.9 | 0.7% |
| EMEA | $55.2 | $52.6 | $2.5 | 4.8% |
| APAC | $49.2 | $49.3 | ($0.2) | (0.3%) |
| ROW | $22.4 | $23.9 | ($1.5) | (6.2%) |
| Total | $799.5 | $746.6 | $52.8 | 7.1% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $215.7 | |
| Cost of Sales | $66.8 | 31% |
| General and Admin | $136.5 | 63.3% |
| R & D | $18.8 | 8.7% |
| R & D | $18.8 | 8.7% |
| Other | $22.7 | 10.5% |
| Net Earnings | ($29.1) | (13.5%) |
Orthofix Medical reported 4Q24 orthopedic sales of $215.7 million, up 7.6% compared to the fourth quarter of 2023. For the full year, the company generated $799.5 million, up 7.1% compared to the prior year.
Sales from Orthofix's trauma and bone growth therapy businesses were the highest in company history. Placements of the 7D navigation...
Orthofix Medical reported 4Q24 orthopedic sales of $215.7 million, up 7.6% compared to the fourth quarter of 2023. For the full year, the company generated $799.5 million, up 7.1% compared to the prior year.
Sales from Orthofix’s trauma and bone growth therapy businesses were the highest in company history. Placements of the 7D navigation system grew 30% compared to last year, with a 150% increase in the number of earn-out agreements. Additionally, spinal implant sales in the U.S. grew 12% with the top six implant systems growing 24%.
The company decided to phase out the M6 artificial disc, which had become a headwind for sales in recent years.
Despite the product’s Level 2 IDE study, Orthofix did not see increased demand for the line. The M6 line generated $23.4 million in 2024, or just over 5% of the company’s spine-related sales.
“We will also be discontinuing the M6, the artificial cervical disc and the M6L artificial lumbar disc product lines,” said Orthofix CFO Julie Andrews. “This product phaseout is in line with our commitment to direct resources to more profitable growth opportunities. It is another milestone in our transformation and supports our strategic focus on driving profitable growth in areas where we have a differentiated advantage.”
Excluding M6 sales, Orthofix expects revenue between $818 million and $826 million in 2025, representing 6.5% growth at the midpoint.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 4Q24 | 4Q23 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $73.0 | $68.3 | $4.7 | 6.8% |
| Trauma | $35.8 | $30.6 | $5.1 | 16.8% |
| Orthobiologics | $38.3 | $38.3 | ($0.0) | (0%) |
| Enabling Technology | $4.8 | $4.4 | $0.4 | 8.3% |
| Other (Bone Growth Therapies) | $63.9 | $58.8 | $5.1 | 8.6% |
| Total | $215.7 | $200.4 | $15.2 | 7.6% |
| Segment | FY24 | FY23 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $285.9 | $266.3 | $19.6 | 7.4% |
| Trauma | $124.2 | $115.3 | $8.9 | 7.7% |
| Orthobiologics | $143.3 | $141.1 | $2.2 | 1.6% |
| Enabling Technology | $12.6 | $11.3 | $1.3 | 11.3% |
| Other (Bone Growth Therapies) | $233.4 | $212.5 | $20.9 | 9.8% |
| Total | $799.5 | $746.6 | $52.9 | 7.1% |
Orthopedic Sales by Geography
| Region | 4Q24 | 4Q23 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $179.2 | $166.9 | $12.3 | 7.4% |
| OUS | $36.4 | $33.5 | $2.9 | 8.7% |
| EMEA | $15.7 | $14.3 | $1.4 | 10.1% |
| APAC | $14.3 | $12.7 | $1.6 | 12.5% |
| ROW | $6.4 | $6.5 | ($0.1) | (1.6%) |
| Total | $215.7 | $200.4 | $15.2 | 7.6% |
| Region | FY24 | FY23 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $672.8 | $620.8 | $52.0 | 8.4% |
| OUS | $126.7 | $125.8 | $0.9 | 0.7% |
| EMEA | $55.2 | $52.6 | $2.5 | 4.8% |
| APAC | $49.2 | $49.3 | ($0.2) | (0.3%) |
| ROW | $22.4 | $23.9 | ($1.5) | (6.2%) |
| Total | $799.5 | $746.6 | $52.8 | 7.1% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $215.7 | |
| Cost of Sales | $66.8 | 31% |
| General and Admin | $136.5 | 63.3% |
| R & D | $18.8 | 8.7% |
| R & D | $18.8 | 8.7% |
| Other | $22.7 | 10.5% |
| Net Earnings | ($29.1) | (13.5%) |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
